LMR Partners LLP Lowers Position in Axonics, Inc. (NASDAQ:AXNX)

LMR Partners LLP decreased its stake in Axonics, Inc. (NASDAQ:AXNX) by 32.3% in the third quarter, HoldingsChannel.com reports. The institutional investor owned 269,863 shares of the company’s stock after selling 128,701 shares during the period. LMR Partners LLP’s holdings in Axonics were worth $18,782,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in AXNX. Entropy Technologies LP bought a new position in shares of Axonics during the 3rd quarter valued at approximately $395,000. Wolverine Asset Management LLC boosted its position in shares of Axonics by 7.8% in the third quarter. Wolverine Asset Management LLC now owns 45,491 shares of the company’s stock worth $3,166,000 after purchasing an additional 3,300 shares during the period. State of New Jersey Common Pension Fund D increased its stake in shares of Axonics by 5.0% in the third quarter. State of New Jersey Common Pension Fund D now owns 28,852 shares of the company’s stock worth $2,008,000 after purchasing an additional 1,379 shares in the last quarter. QRG Capital Management Inc. increased its stake in shares of Axonics by 21.0% in the third quarter. QRG Capital Management Inc. now owns 17,437 shares of the company’s stock worth $1,214,000 after purchasing an additional 3,022 shares in the last quarter. Finally, Healthcare of Ontario Pension Plan Trust Fund bought a new stake in shares of Axonics during the 2nd quarter valued at $15,080,000. Institutional investors own 99.48% of the company’s stock.

Insider Activity

In related news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction on Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the sale, the chief financial officer now owns 40,362 shares in the company, valued at approximately $2,801,526.42. This represents a 6.83 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 1.85% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research note on Friday, November 8th. Eight analysts have rated the stock with a hold rating, According to MarketBeat, Axonics presently has a consensus rating of “Hold” and a consensus price target of $71.00.

Axonics Trading Up 0.8 %

Shares of NASDAQ:AXNX opened at $70.98 on Monday. The company has a 50-day moving average price of $69.87 and a 200 day moving average price of $68.60. Axonics, Inc. has a 12 month low of $55.09 and a 12 month high of $71.05. The company has a market cap of $3.63 billion, a price-to-earnings ratio of -591.45 and a beta of 0.82.

Axonics Company Profile

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.